DaVita Inc. (DVA) managed to eke out gains of 1.38% in intraday trade. The share price increased by 0.88 points to $64.63. Till last observation, the net money flow was recorded at a negative $(-10.81) million. The total inflow of $17.03 million in upticks was completely overshadowed by an outflow of $27.84 million in downticks, giving the up/down ratio a value of 0.61. The shares have seen a change of 0.12% in the past week.A block trade occurred in the company shares in which the composite value of the upticks was $3.81 million and the composite value in downticks was $16.9 million. The resultant up/down ratio for the block exchange was 0.23. The block trade had a negative money flow of $(-13.09) million.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Shares of DaVita Inc. rose by 0.86% in the last five trading days and 0.67% for the last 4 weeks. DaVita Inc. is up 10.25% in the last 3-month period. Year-to-Date the stock performance stands at 0.67%. DaVita Inc. (NYSE:DVA) rose 1.38% or 0.88 points on Wednesday and made its way into the gainers of the day. After trading began at $63.99 the stock was seen hitting $64.81 as a peak level and $63.76 as the lowest level. The stock ended up at $64.63. The daily volume was measured at 1,474,997 shares. The 52-week high of the share price is $78.77 and the 52-week low is $54.5. The company has a market cap of $12,758 million.
Company has reported several Insider transactions to the SEC, on Aug 11, 2016, Michael David Staffieri (COO, Kidney Care) sold 20,262 shares at 73.09 per share price.On Jul 13, 2016, Jeanine Marie Jiganti (Chief Compliance Officer) sold 1,291 shares at 78.51 per share price.On May 26, 2016, Pamela M Arway (director) sold 10,824 shares at 77.16 per share price.
DaVita HealthCare Partners Inc Last issued its quarterly earnings results on Nov 2, 2016. The company reported $0.95 EPS for the quarter, beating the analyst consensus estimate by $ 0.02. Analyst had a consensus of $0.93. The company had revenue of $3730.58 million for the quarter, compared to analysts expectations of $3723.95 million. The companys revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.12 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Company shares were Downgraded by Robert W. Baird on Dec 13, 2016 to Neutral, Raises Price Target to $ 69 from a previous price target of $68 .
DaVita Inc. is the parent company of DaVita Kidney Care and HealthCare Partners. DaVita Kidney Care is a provider of kidney care, delivering dialysis services for chronic kidney failure and end stage renal disease primarily in the United States. HealthCare Partners manages and operates medical groups and affiliated physician networks primarily in California, Nevada, New Mexico, Florida, Colorado and Washington. DaVita Inc., formerly known as DaVita HealthCare Partners Inc., is headquartered in Denver, Colorado.